Interaction of bispyridinium compounds with the orthosteric binding site of human α7 and Torpedo californica nicotinic acetylcholine receptors (nAChRs)

Toxicology Letters

Volumn 206, Issue 1, 2011, Pages 100-104

  Niessen, K V ^a   Tattersall, J E H ^b   Timperley, C M ^c   Bird, M ^c   Green, C ^b   Seeger, T ^a   Thiermann, H ^a   Worek, F ^a  

^a BUNDESWEHR INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (Germany)

^b Biomedical Sciences   (United Kingdom)

^c Detection Department   (United Kingdom)

Author keywords

Bispyridinium compound; Human 7; Nicotinic acetylcholine receptor; Radioligand binding assay; Torpedo californica

Indexed keywords

ALPHA BUNGAROTOXIN; BIS(PYRIDINIUM OXIME) DERIVATIVE; CARBACHOL; EPIBATIDINE; METHYLLYCACONITINE; NICOTINIC RECEPTOR; ORGANOPHOSPHORUS COMPOUND; PANCURONIUM;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING SITE; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME STRUCTURE; IC 50; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY; RAT; RECEPTOR BINDING; TORPEDO CALIFORNICA;

ACETYLCHOLINESTERASE; ANIMALS; BINDING SITES; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL MEMBRANE; ELECTRIC ORGAN; ERYTHROCYTE MEMBRANE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIGANDS; MOLECULAR STRUCTURE; PROTEIN BINDING; PYRIDINIUM COMPOUNDS; RADIOLIGAND ASSAY; RATS; RECEPTORS, NICOTINIC; TORPEDO; TRANSFECTION;

TORPEDO CALIFORNICA;

EID: 80051815760     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.06.009     Document Type: Article

References (31)

1. Alkondon M., Albuquerque E.X. The nonoxime bispyridinium compound SAD-128 alters the kinetic properties of the nicotinic acetylcholine receptor ion channel: a possible mechanism for antidotal effects. J. Pharmacol. Exp. Ther. 1989, 250:842-852.
2. Arias H.R., Xing H., MacDougall K., Blanton M.P., Soti F., Kem W.R. Interaction of benzylidene-anabaseine analogues with agonist and allosteric sites on muscle nicotinic acetylcholine receptors. Br. J. Pharmacol. 2009, 157:320-330.
3. Ayers J.T., Dwoskin L.P., Deaciuc A.G., Grinevich V.P., Zhu J., Crooks P.A. Bis-azaaromatic quaternary ammonium analogues: ligands for α4β2 and α7 subtypes of neuronal nicotinic receptors. Bioorg. Med. Chem. Lett. 2002, 12:3067-3071.
4. Bruns R.F., Lawson-Wendling K., Pugsley T.A. A rapid filtration assay for soluble receptors using polyethylenimine-treated filters. Anal. Biochem. 1983, 132:74-81.
5. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22:3099-3108.
6. Dodge J.T., Mitchell C., Hanahan D.J. The preparation and chemical characteristics of haemoglobin-free ghosts of human erythrocytes. Arch. Biochem. Biophys. 1963, 100:119-130.
7. Elliot J., Blanchard S.G., Wu W., Miller J., Strader C.D., Hartig P., Moore H.-P., Racs J., Raftery M.A. Purification of Torpedo californica post-synaptic membranes and fractionation of their constituent proteins. Biochem. J. 1980, 185:667-677.
8. Eyer P., Worek F., Kiderlen D., Sinko G., Stuglin A., Simeon-Rudolf V., Reiner E. Molar absorptions coefficients for the reduced Ellman reagent: reassessment. Anal. Biochem. 2003, 312:224-227.
9. Eyer P., Worek F. Oximes. Chemical Warfare Agents: Toxicology and Treatment 2007, 305-329. John Wiley & Sons Ltd., Chichester. T.C. Marrs, R.L. Maynard, F.R. Sidell (Eds.).
10. Fagerlund M.J., Eriksson L.I. Current concepts in neuromuscular transmission. Br. J. Anaesth. 2009, 103:108-114.
11. Gerzanich V., Peng X., Wang F., Wells G., Anand R., Fletcher S., Lindstrom J. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol. Pharmacol. 1995, 48:774-782.
12. Gopalakrishnan M., Buisson B., Touma E., Giordano T., Campbell J.E., Hu I.C., Donnelly-Roberts D., Arneric S.P., Bertrand D., Sullivan J.P. Stable expression and pharmacological properties of the human α7 nicotinic acetylcholine receptor. Eur. J. Pharmacol. (Mol. Pharmacol. Sect.) 1995, 290:237-246.
13. Grubič Z., Tomažič A. Mechanism of action of HI-6 on soman inhibition of acetylcholinesterase in preparation of rat and human skeletal muscle; comparison to SAD-128 and PAM-2. Arch. Toxicol. 1989, 63:68-71.
14. Harris L.W., Heyl W.C., Siltcher D.L., Broomfield C.A. Effects of 1,1'-oxidimethylene bis-(4-tert-butylpyridinium chloride) (SAD-128) and decamethonium on reactivation of soman- and sarin-inhibited cholinesterase by oximes. Biochem. Pharmacol. 1977, 27:757-761.
15. Kawai H., Dunn S.M.J., Raftery M.A. Epibatidine binds to four sites on Torpedo nicotinic acetylcholine receptor. Biochem. Biophys. Res. Commun. 2008, 366:834-839.
16. Lukas R.J., Morimoto H., Hanley M.R., Bennett E.L. Radiolabeled α-bungarotoxin derivatives: kinetic interaction with nicotinic acetylcholine receptors. Biochemistry 1981, 20:7373-7378.
17. Macallan D.R.E., Lunt G.G., Wonnacott S., Swanson K.L., Rapoport H., Albuquerque E.X. Methyllycaconitine and (+)-anatoxin-α differentiate between nicotinic receptors in vertebrate and invertebrate nervous systems. FEBS Lett. 1988, 226:357-363.
18. Millar N.S. Assembly and subunit diversity of nicotinic acetylcholine receptors. Biochem. Soc. Trans. 2003, 31:869-874.
19. Quik M., Choremis J., Komourian J., Lukas R.J., Puchacz E. Similarity between rat brain nicotinic α-bungarotoxin receptors and stably expressed α-bungarotoxin binding sites. J. Neurochem. 1996, 67:145-154.
20. Rovati E. Rational experimental design and data analysis for ligand binding studies: tricks, tips and pitfalls. Pharmacol. Res. 1993, 28:277-299.
21. Schoene K., Oldiges H. Die Wirkungen von Pyridiniumsalzen gegenüber Tabun- und Sarinvergiftungen in vivo und in vitro. Arch. Int. Pharmacodyn. 1973, 204:110-123.
22. Sheridan R.D., Smith A.P., Turner S.R., Tattersall J.E.H. Nicotinic antagonists in the treatment of nerve agent intoxication. J. R. Soc. Med. 2005, 98:114-115.
23. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150:76-85.
24. Štalc A., Šentjurc M. A contribution to the mechanism of action of SAD-128. Biochem. Pharmacol. 1990, 40:2511-2517.
25. Steiner F., Ghose S., Thomet U. Recombinant cell lines stably expressing functional ion channels. Analgesia. Methods and Protocols. Methods in Molecular Biology 2010, 209-221. A. Szallasi (Ed.).
26. Thiermann H., Seeger T., Gonder S., Herkert N., Antkowiak B., Zilker T., Eyer F., Worek F. Assessment of neuromuscular dysfunction during poisoning by organophosphorus compounds. Chem. Biol. Interact. 2010, 187:265-269.
27. Timperley C.M., Bird M., Heard S.C., Notman S., Read R.W., Tattersall J.E.H., Turner S.R. Fluorinated pyridine derivatives. Part 1. The synthesis of some mono- and bis-quaternary pyridine salts of potential use in the treatment of nerve agent poisoning. J. Fluorine Chem. 2005, 126:1160-1165.
28. Turner, S., 2007. Noncompetitive nicotinic acetylcholine receptor antagonists for the treatment of anticholinesterase poisoning. Ph.D. thesis, University of Southampton, UK.
29. Worek F., Mast U., Kiderlen D., Diepold C., Eyer P. Improved determination of acetylcholinesterase activity in human whole blood. Clin. Chem. Acta 1999, 288:73-90.
30. Worek F., Reiter G., Eyer P., Szinicz L. Reactivation kinetics of acetylcholinesterase from different species inhibited by highly toxic organophosphates. Arch. Toxicol. 2002, 76:523-529.
31. Worek F., Thiermann H., Szinicz L. Reactivation and aging kinetics of human acetylcholinesterase inhibited by organophosphonylcholines. Arch. Toxicol. 2004, 78:212-217.